Last reviewed · How we verify

Neoral® (Cyclosporine)

Wyeth is now a wholly owned subsidiary of Pfizer · FDA-approved active Small molecule

Neoral® (Cyclosporine) is a Calcineurin inhibitor Small molecule drug developed by Wyeth is now a wholly owned subsidiary of Pfizer. It is currently FDA-approved for Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas), Severe active rheumatoid arthritis, Severe psoriasis.

Cyclosporine inhibits T-cell activation by binding to cyclophilin and blocking calcineurin-mediated transcription of interleukin-2 and other cytokines.

Cyclosporine inhibits T-cell activation by blocking calcineurin, a phosphatase required for IL-2 production and T-cell proliferation. Used for Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas), Rheumatoid arthritis, Psoriasis.

At a glance

Generic nameNeoral® (Cyclosporine)
SponsorWyeth is now a wholly owned subsidiary of Pfizer
Drug classCalcineurin inhibitor
TargetCalcineurin (via cyclophilin binding)
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Cyclosporine forms a complex with the intracellular protein cyclophilin, which then inhibits the phosphatase calcineurin. This prevents dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells), thereby suppressing the transcription of IL-2 and other pro-inflammatory cytokines essential for T-cell proliferation and activation. The result is selective immunosuppression without affecting B-cell or antibody production directly.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Neoral® (Cyclosporine)

What is Neoral® (Cyclosporine)?

Neoral® (Cyclosporine) is a Calcineurin inhibitor drug developed by Wyeth is now a wholly owned subsidiary of Pfizer, indicated for Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas), Severe active rheumatoid arthritis, Severe psoriasis.

How does Neoral® (Cyclosporine) work?

Cyclosporine inhibits T-cell activation by binding to cyclophilin and blocking calcineurin-mediated transcription of interleukin-2 and other cytokines.

What is Neoral® (Cyclosporine) used for?

Neoral® (Cyclosporine) is indicated for Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas), Severe active rheumatoid arthritis, Severe psoriasis, Nephrotic syndrome (minimal change disease), Severe atopic dermatitis.

Who makes Neoral® (Cyclosporine)?

Neoral® (Cyclosporine) is developed and marketed by Wyeth is now a wholly owned subsidiary of Pfizer (see full Wyeth is now a wholly owned subsidiary of Pfizer pipeline at /company/wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer).

What drug class is Neoral® (Cyclosporine) in?

Neoral® (Cyclosporine) belongs to the Calcineurin inhibitor class. See all Calcineurin inhibitor drugs at /class/calcineurin-inhibitor.

What development phase is Neoral® (Cyclosporine) in?

Neoral® (Cyclosporine) is FDA-approved (marketed).

What are the side effects of Neoral® (Cyclosporine)?

Common side effects of Neoral® (Cyclosporine) include Nephrotoxicity/renal dysfunction, Hypertension, Tremor, Gingival hyperplasia, Hirsutism, Headache.

What does Neoral® (Cyclosporine) target?

Neoral® (Cyclosporine) targets Calcineurin (via cyclophilin binding) and is a Calcineurin inhibitor.

Related